Data on cholesterol drug fenofibrate lead to FDA advisory

11/9/2011 | Medscape (free registration)

Data from the ACCORD Lipid trial showed the cholesterol-lowering drug fenofibric acid or fenofibrate may not reduce the risk of major cardiovascular events, leading the FDA to issue a safety communication and update prescribing information. The agency also asked for a trial to study the medication's cardiovascular effects in patients on statins.

View Full Article in:

Medscape (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Stop Loss Sales Executive
Blue Cross Blue Shield of Massachusetts
Boston, MA
Senior Director, Research
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide